Arlington Capital Partners Makes Majority Investment in Afton Scientific

Arlington Capital Partners Acquires TEAM Technologies

November 26, 2024

Medical Devices

Arlington Capital Partners has acquired TEAM Technologies, a Morristown, Tennessee–headquartered medical device manufacturer and strategic supply‑chain solutions provider, from Clearlake Capital Group for an undisclosed sum. Arlington plans to build on TEAM Tech’s vertically integrated manufacturing footprint and accelerate growth through organic investment and strategic add‑on M&A to strengthen healthcare supply chains and customer capabilities.

Arlington Capital Partners Acquires Charles River's Avian Vaccine Services to Form AVS Bio

January 5, 2023

Biotechnology

Arlington Capital Partners has acquired Charles River Laboratories' Avian Vaccine Services business to form a standalone company, AVS Bio, serving the biologic manufacturing and bioprocessing markets. AVS Bio, headquartered in Norwich, Connecticut, supplies SPF eggs, antigens, cell products and diagnostic/manufacturing support services and has ~250 employees across 20+ facilities; Fairmount Partners advised Charles River on the sale.

Arlington Capital Partners Acquires Millstone Medical Outsourcing

January 11, 2022

Medical Devices

Arlington Capital Partners, a Washington, DC-based private equity firm, has acquired Millstone Medical Outsourcing, a Fall River, Massachusetts-based provider of post-manufacturing, quality-critical services and supply chain logistics to medical device and pharmaceutical manufacturers. Selling shareholders included Schooner Capital; Arlington said it will provide strategic and capital support to accelerate Millstone's organic growth and pursue strategic acquisitions.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Arlington Capital Partners Makes Majority Investment in Everest Clinical Research Corporation

December 7, 2020

Healthcare Services

Washington, D.C.-based private equity firm Arlington Capital Partners has made a majority investment in Toronto-headquartered Everest Clinical Research Corporation, with Everest's founding shareholders and senior management rolling equity and continuing to lead the company. Everest is a full-service contract research organization (CRO) with ~300 employees across Toronto, Little Falls (NJ) and Shanghai; Arlington will support expansion of service lines, capabilities and headcount to drive growth.

Arlington Capital Partners Acquires J&J Worldwide Services

July 8, 2020

Government & Public Sector

Arlington Capital Partners has completed the acquisition of J&J Worldwide Services in partnership with the Company's existing management team. Headquartered in Austin, Texas, J&J provides mission-essential facility, maintenance and healthcare support services to U.S. federal government sites and collectively employs over 3,200 people across more than 270 locations; the Voudouris family and senior management participated in the transaction.